AstraZeneca: FDA Gives Orphan Drug Status to Two Liver Cancer Drugs

Date : 01/20/2020 @ 7:48AM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 50.17  1.23 (2.51%) @ 1:00AM
After Hours
Last Trade
Last $ 50.17 ◊ 0.00 (0.00%)

AstraZeneca: FDA Gives Orphan Drug Status to Two Liver Cancer Drugs

Astrazeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Astrazeneca Charts.
   By Carlo Martuscelli 

AstraZeneca PLC (AZN.LN) said Monday that two of its medicines were granted orphan drug status by the U.S. Food and Drug Administration for the treatment of a common type of liver cancer.

The designation is awarded to drugs that are intended to treat rare disease and provides benefits such as market exclusivity and faster regulatory approvals.

Imfinzi and tremelimumab were given orphan drug status as treatments for hepatocellular carcinoma, or HCC. Imfinzi is already approved for other types of cancer, while tremelimumab is currently being investigated as a potential treatment.

The two drugs are being jointly studied in the phase 3 Himalaya clinical trial as treatments for a type of inoperable and advanced HCC.


Write to Carlo Martuscelli at; @carlomartu


(END) Dow Jones Newswires

January 20, 2020 02:33 ET (07:33 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.